Also listed on Inozyme Pharma, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Collateral for a security interest recorded Apr 27, 2026 (Citibank, N.A.).
Term ends Mar 11, 2031 · High confidence
20-year base term ends Mar 11, 2031
Held by Biomarin Pharmaceutical Inc.
Filed Apr 23, 2013 as application 13/583,973 · Granted Sep 30, 2014
Base term, 20 years from filing
Today
2011
2031
Clock starts
Mar 11, 2011
Mar 11, 2011
Term ends
Mar 11, 2031
Mar 11, 2031
Granted
Sep 30, 2014
Sep 30, 2014
base term
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
9
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Mar 11, 2011, when application PCT/US2011/028233, the earliest non-provisional in its chain, was filed (this one was filed Apr 23, 2013) | Mar 11, 2031 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Mar 11, 2031 | High confidence |
This family
| Application PCT/US2011/028233 | PCT application no patent term | no patent term |
| US 8,846,603 | this patent Mar 2031 | Mar 2031 |
| Application 14/004,294 | Abandoned not computed | not computed |
| US 9,540,621 | In force no later than Mar 2031 | no later than Mar 2031 |
| Application 15/417,590 | Abandoned not computed | not computed |
| Application 17/105,245 | Abandoned not computed | not computed |
| Application 17/819,065 | Abandoned not computed | not computed |
| Application 19/183,431 | Pending not computed | not computed |
8 of 9 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Apr 23, 2013 Reel 30267, frame 730 | Quinn, Anthony; Harvey, Alex J.; Xia, Zhinan | Synageva Biopharma Corp. | Assignment of Assignor's Interest |
| Nov 15, 2016 Reel 40329, frame 154 | Synageva Biopharma Corp.; Galaxy Merger Sub LLC | Alexion Pharma LLC | Merger and Change of Name |
| Nov 17, 2016 Reel 40361, frame 470 | Alexion Pharma LLC | Alexion Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Nov 23, 2020 Reel 54449, frame 251 | Alexion Pharmaceuticals, Inc. | Inozyme Pharma, Inc. | Assignment of Assignor's Interest |
| Aug 9, 2021 Reel 57127, frame 791 | Alexion Pharma LLC | Alexion Pharmaceuticals, Inc. | Corrective Assignment to Correct the Execution Date of the Assignment Previously Recorded at Reel: 040361 Frame: 0470. Assignor(S) Hereby Confirms the Assignment. |
| Nov 25, 2025 Reel 73707, frame 488 | Inozyme Pharma, Inc. | Biomarin Pharmaceutical Inc. | Assignment of Assignor's Interest |
| Apr 27, 2026 Reel 75493, frame 968 | Biomarin Pharmaceutical Inc.; Amicus Therapeutics, Inc. | Citibank, N.A., as Collateral Agent | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Mar 2031
Term ends Mar 11, 2031. No further fees fall due before then
Citations
31
later US patents cite this one
That is top 25% of utility patents granted in 2014 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.